Todos Medical Ltd. announced biomarker data from its majority-owned joint venture 3CL Pharma Ltd.'s Phase 2 clinical trial of Tollovir in hospitalized COVID-19 patients. The data showed a positive correlation between the clinical data announced for Tollovir on January 27, 2022 and biomarkers associated with acute phase immune response, inflammation, blood clotting and immune response to COVID-19. Additionally, renal and hepatic biomarker data showed no signals of treatment-associated risk with Tollovir therapy.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | -99.50% |
1st Jan change | Capi. | |
---|---|---|
-99.50% | 3.32K | |
-28.41% | 9.96B | |
+32.66% | 3.76B | |
-20.73% | 2.37B | |
-11.15% | 2.27B | |
-22.76% | 1.58B | |
+59.24% | 1.31B | |
-1.31% | 750M | |
+21.17% | 575M | |
-28.06% | 525M |
- Stock Market
- Equities
- TOMDF Stock
- News Todos Medical Ltd.
- Todos Medical Ltd. Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients